HSBC Downgrades Novo Nordisk Stock to ‘Hold’ Amidst Analyst Revisions
Financial markets are abuzz following HSBC’s recent decision to downgrade Novo Nordisk A/S (NYSE:NVO) from a ‘buy’ to a ‘hold’ rating, a move that sent ripples through…
Merck & Co. Faces Q3 Earnings Downgrade: What Investors Need to Know
Leerink Partners has cast a shadow on Merck & Co.’s third-quarter 2025 earnings outlook, signaling a notable adjustment in their financial projections for the pharmaceutical giant. This…